EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genome‐Wide Screening in Haploid Stem Cells Reveals Synthetic Lethality Targeting MLH1 and TP53 Deficient Tumours

Rivki Cashman, Guy Haim-Abadi, Elyad Lezmi, Hagit Philip, Jonathan Nissenbaum, Ruth Viner-Breuer, Chen Kozulin, Tamar Golan-Lev, Aseel Gadban, Shiri Spinner-Potesky, Ofra Yanuka, Oded Kopper und 1 weitere

Cell Proliferation · 2025

DOI: 10.1111/cpr.13788 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Rivki Cashman und 12 weiteren Autor:innen. Beteiligte Einrichtung: NewStem LTD, Jerusalem, Israel. Hauptthemen laut MEDLINE: MutL Protein Homolog 1, Tumor Suppressor Protein p53, Synthetic Lethal Mutations, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation, NewStem LTD, Azrieli Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synthetic lethality is defined as a type of genetic interaction where the combination of two genetic events results in cell death, whereas each of them separately does not. Synthetic lethality can be a useful tool in personalised oncology. MLH1 is a cancer‐related gene that has a central role in DNA mismatch‐repair and TP53 is the most frequently mutated gene in cancer. To identify genetic events that can lead to tumour death once either MLH1 or TP53 is mutated, a genome‐wide genetic screening was performed. Thus, mutations in all protein‐coding genes were introduced into haploid human embryonic stem cells (hESCs) with and without loss‐of‐function mutations in the MLH1 or TP53 genes. These experiments uncovered a list of putative hits with EXO1 , NR5A2 , and PLK2 genes for MLH1, and MYH10 gene for TP53 emerging as the most promising candidates. Synthetic lethal interactions of these genes were validated genetically or chemically using small molecules that inhibit these genes. The specific effects of SR1848, which inhibits NR5A2, ON1231320 or BI2536, which inhibits PLK2, and blebbistatin, which inhibits MYH10, were further validated in cancer cell lines. Finally, animal studies with CCL xenografts showed the selective effect of the small molecule BI2536 on MLH1 ‐null tumours and of blebbistatin on TP53‐ mutated tumours. Thus, demonstrating their potential for personalised medicine, and the robustness of genetic screening in haploid hESCs in the context of cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutL Protein Homolog 1Tumor Suppressor Protein p53Synthetic Lethal MutationsNeoplasmsHumansAnimalsHaploidyMiceCell Line, TumorHuman Embryonic Stem Cells

Substanzen

MutL Protein Homolog 1Tumor Suppressor Protein p53MLH1 protein, humanTP53 protein, human

Autor:innen und Institutionen

  • NewStem LTD, Jerusalem, Israel.
  • The Azrieli Center for Stem Cells and Genetic Research, Department of Genetics, Silberman Institute of Life Sciences, The Hebrew University, Jerusalem, Israel.

ORCID-Profile: Nissim Benvenisty

Förderung

  • Israel Science Foundation
  • NewStem LTD
  • Azrieli Foundation

Zitieren

APA

Cashman, R., Haim-Abadi, G., Lezmi, E., Philip, H., Nissenbaum, J., Viner-Breuer, R., Kozulin, C., Golan-Lev, T., Gadban, A., Spinner-Potesky, S., Yanuka, O., Kopper, O., & Benvenisty, N. (2025). Genome‐Wide Screening in Haploid Stem Cells Reveals Synthetic Lethality Targeting MLH1 and TP53 Deficient Tumours. Cell Proliferation. https://doi.org/10.1111/cpr.13788

Vancouver

Cashman R, Haim-Abadi G, Lezmi E, Philip H, Nissenbaum J, Viner-Breuer R, et al. Genome‐Wide Screening in Haploid Stem Cells Reveals Synthetic Lethality Targeting MLH1 and TP53 Deficient Tumours. Cell Proliferation. 2025. doi:10.1111/cpr.13788

BibTeX
@article{Cashman2025,
  author = {Cashman, Rivki and Haim-Abadi, Guy and Lezmi, Elyad and Philip, Hagit and Nissenbaum, Jonathan and Viner-Breuer, Ruth and Kozulin, Chen and Golan-Lev, Tamar and Gadban, Aseel and Spinner-Potesky, Shiri and Yanuka, Ofra and Kopper, Oded and Benvenisty, Nissim},
  title = {Genome‐Wide Screening in Haploid Stem Cells Reveals Synthetic Lethality Targeting MLH1 and TP53 Deficient Tumours},
  journal = {Cell Proliferation},
  year = {2025},
  doi = {10.1111/cpr.13788}
}
Kostenlos starten →